Skip to main content
Log in

Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

There is a significantly increased risk of pregnancy complications in women with anti-phospholipid syndrome (APS). The risk is further heightened in those with previous arterial or venous thromboembolism and so-called ‘triple positivity’ for anti-phospholipid antibodies (i.e., when lupus anticoagulant, and anti-cardiolipin (aCL) and anti-β2 glycoprotein-I (anti-β2Gp-I) antibodies are all detected). Management of these cases is extremely difficult and little is available in the medical literature to guide therapy. This report describes the use of regular plasma exchanges (PEx) to bring about a successful pregnancy outcome in a woman with secondary APS and previous recurrent miscarriages. The patient was also anticoagulated with enoxaparin and administered aspirin, prednisolone, azathioprine and hydroxychloroquine. Through regular PEx and immunomodulation therapy, levels of aCL and anti-β2Gp-I antibodies were monitored and documented to fall as pregnancy progressed. Although the outcome in this case was successful, further experience is required before this regimen can be accepted as the standard of care for these patients at very high risk of pregnancy loss.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M (2012) British Committee for Standards in Haematology: guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 157:47–58

    Article  PubMed  CAS  Google Scholar 

  2. Ruffatti A, Tonello M, Del Ross T, Cavazzana A, Grava C, Noventa F, Tona F, Iliceto S, Pengo V (2006) Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 96:337–341

    PubMed  CAS  Google Scholar 

  3. Lateef A, Petri M (2013) Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 27:435–447

    Article  PubMed  Google Scholar 

  4. Pengo V (2011) APS—controversies in diagnosis and management, critical overview of current guidelines. Thromb Res 127(Suppl 3):S51–S52

    Article  PubMed  CAS  Google Scholar 

  5. Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17

    Article  PubMed  CAS  Google Scholar 

  6. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376:1498–1509

    Article  PubMed  CAS  Google Scholar 

  7. Ruffatti A, Marson P, Pengo V, Favaro M, Tonello M, Bortolati M, Minucci D, De Silvestro G (2007) Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 6:196–202

    Article  PubMed  Google Scholar 

  8. Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guideline. Chest 141(Suppl 2):24S–43S

    Google Scholar 

  9. Petri M (2011) Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 13:77–80

    Article  PubMed  CAS  Google Scholar 

  10. Tincani A, Bazzani C, Zingarelli S, Lojacono A (2008) Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 34:267–273

    Article  PubMed  CAS  Google Scholar 

  11. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28

    Article  PubMed  CAS  Google Scholar 

  12. Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, Lou W, Fortin PR (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62:863–868

    Article  PubMed  CAS  Google Scholar 

  13. Reverberi R, Reverberi L (2007) Removal kinetics of therapeutic apheresis. Blood Transfus 5:164–174

    PubMed  PubMed Central  Google Scholar 

  14. Zar T, Kaplan AA (2008) Predictable removal of anticardiolipin antibody by therapeutic plasma exchange (TPE) in catastrophic antiphospholipid antibody syndrome (CAPS). Clin Nephrol 70:77–81

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wai Khoon Ho.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rose, H.L., Ho, W.K. Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies. J Thromb Thrombolysis 38, 453–456 (2014). https://doi.org/10.1007/s11239-014-1080-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-014-1080-7

Keywords

Navigation